Apart from a potential selection bias for pegvisomant in patients with more risk factors for T2DM or worse metabolic control, the introduction in recent years of GLP1 receptor agonists (36) and SGLT2 inhibitors allows for improving and simplifying metabolic control in these patients, as they are already being monitored by an endocrinology specialist who can coordinate multimodal care for T2DM (37). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.